Letter to the Editors
On the importance of blood sampling for ciclosporin pharmacokinetic studies
Article first published online: 5 FEB 2013
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Special Issue: Nutraceuticals Themed Section
Volume 75, Issue 3, pages 869–870, March 2013
How to Cite
Bleyzac, N. (2013), On the importance of blood sampling for ciclosporin pharmacokinetic studies. British Journal of Clinical Pharmacology, 75: 869–870. doi: 10.1111/j.1365-2125.2012.04414.x
- Issue published online: 5 FEB 2013
- Article first published online: 5 FEB 2013
- Accepted manuscript online: 6 AUG 2012 08:06AM EST
- Manuscript Accepted: 24 JUL 2012
- Manuscript Received: 11 JUL 2012
We read the interesting paper recently published by Wilhelm et al . Measured blood concentrations of ciclosporin (CsA) reported in Figure 2 seem very high with regards to the daily dose administered. This could be due to the method of blood sampling in some patients. Indeed, the authors mentioned that blood was collected from a peripheral venous cannula or a central venous line. Discarding the first 5 ml seems not to be sufficient to obtain non-biased CsA measurements from a central venous catheter. Hence, there have been several reports of falsely high CsA concentrations due to the absorption of CsA in the material (PVC, polyurethane or other) of the central venous catheter wall, after the catheter was used for CsA administration [2-4]. Desorption of CsA from catheters and lines may last a long time and CsA can be released several weeks after intravenous administration is stopped . In our experience, patients receiving oral CsA can present with spoiled CsA concentrations even if the catheter receives a lot of others infusions after CsA. In theses conditions, blood concentrations used in the study of Wilheim et al. would not allow the accurate determination of pharmacokinetic parameters values. The authors justify the high AUC values obtained in their study compared with previous published data with the inhibition of the CsA metabolism by fluconazole, used for prophylaxis of fungal infections. Fluconazole was given at 50 mg day−1. As fluconazole is not the most potent inhibitor among azole antifungals and furthermore, because CYP3A4 inhibition by azole antifungals is concentration-dependent [6, 7], this dosage regimen may not to lead to a significant increase in CsA blood concentrations.
The site of blood sampling for CsA measurement in haematopoietic stem cell patients should be carefully selected to avoid false results. This is valuable for studies on CsA administered intravenously, and also orally, as these patients often receive intravenous CsA before being able to swallow capsules.
All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.
All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare; no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.